PURPOSE: To define the features and course of myelokathexis, a rare congenital neutropenia resulting from impaired release of granulocytes from bone marrow. METHODS: The clinical features ...

X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced that its Marketing Authorization Application (MAA) for mavorixafor for the ...